Development of new inhibitors targeting histone deacetylases (HDACs) with improved efficacy for solid tumor therapy is urgently needed. Here, we report the development of a novel HDAC inhibitor TMU-35435 and verify it as a single agent and in combination treatment with DNA demethylation reagent 5-aza-2 0 -deoxycytidine (5-aza-dC) in lung cancer preclinical models.
TMU-35435 exerted cancer-specific cytotoxicity via mitochondria-mediated apoptosis. Expression microarrays revealed a unique TMU-35435-induced gene networks enriched in biological processes, including "negative regulation of cell proliferation" and "Wnt receptor signaling pathway" compared to FDA-approved HDAC inhibitor SAHA. TMU-35435 inhibited tumor growth with good pharmacokinetic properties and safety features in lung orthotopic and subcutaneously implanted xenograft models. TMU-35435 and 5-aza-dC showed synergistic antitumor effects through reactivation of tumor suppressor genes and those genes encoding negative regulators of Wnt signaling pathway in vitro and in vivo. Some genes showed additive inhibition of DNA methylation upon TMU-35435 and 5-aza-dC combined treatment. Our findings suggested that TMU-35435 is a potential HDAC inhibitor for lung cancer treatment as a single agent and in combination with 5-aza-dC.
Overexpression and/or increased activity of histone deacetylases (HDACs) in cancer cells and low basal level in normal cells make HDACs a potential therapeutic target for cancer treatment. 1, 2 For example, SAHA (vorinostat, Zolinza V R ) and depsipeptide (romidepsin, Istodax V R ) have been approved by US FDA for the treatment of cutaneous T-cell lymphoma. 3, 4 Numerous clinical trials have been completed or are ongoing in both hematological and solid malignancies using a wide variety of HDAC inhibitors as well as in combination with other agents. 5, 6 Although there have been some promising developments in hematological tumors, results in solid tumors have been unsatisfactory. In addition, resistances to HDAC inhibitors have been reported. [7] [8] [9] Aberrant gene silencing in cancer can be achieved by both histone deacetylation and DNA methylation, thus providing a rationale for targeting HDACs or DNA methyltransferases (DNMTs) as a therapeutic strategy against cancer. [10] [11] [12] Combination of HDAC inhibitor and DNMT inhibitor such as 5-aza-2 0 -deoxycytidine (5-aza-dC, Dacogen V R , decitabine) shows effectiveness against lung cancer and acute myelogenous leukemia. 13, 14 Such a combination synergistically reactivates silenced tumor suppressor genes (TSGs) in treated cancer cells. 15, 16 It has been reported that HDAC inhibitor-induced apoptosis is greatly enhanced in the presence of DNMT inhibitor and may be related to enhancement of histone acetylation. 17, 18 Some in vitro studies have shown additive or synergistic inhibition of DNA synthesis, loss of clonogenicity and induction of apoptosis in nonsmall-cell lung cancer (NSCLC) cell lines treated with 5-aza-dC and HDAC inhibitor (reviewed in Ref. 19 ). Several ongoing clinical trials evaluating combinational treatment with HDACs and DNMTs inhibitors have targeted specific solid tumor malignancies, including NSCLC (NCT00387465 and NCT01886573). 20, 21 Discovery of new HDAC inhibitor with improved efficacy or development of new combinatorial therapeutics for solid tumor is an urgently needed. Therefore, this study evaluated the antitumor effects and affected signal pathways of a novel HDAC inhibitor, namely TMU-35435, using in vitro and in vivo models of human NSCLC. Moreover, the potential combination effects of TMU-35435 with 5-aza-dC on reactivation of TSGs, leading to cancer regression, were evaluated. The goal was to develop an HDAC inhibitor with low IC 50 to treat NSCLC tumors with minimal side effects in preclinical models.
Material and Methods

Preparation of TMU-35435
The complete chemical name of TMU-35435 is N-hydroxy-6-(5-methyl-4-acridinecarbamoyl) hexanamide. Request for the compound should be sent to wjhuang@tmu.edu.tw.
Cell lines and culture conditions
Normal human lung cell lines MRC5 and IMR90, human lung adenocarcinoma cell line A549 were purchased from American Tissue Culture Company (Rockville, MD). A549-Oct4 was established by stable overexpression of Oct4 stemness transcription factor as demonstrated in our previous study. 22 Human lung adenocarcinoma cell line PC-14 was obtained from Dr. Pan-Chyr Yang (Department of Internal Medicine, Medical College, National Taiwan University, Taipei, Taiwan). Luciferase-expressing human large cell lung cancer cell line H460-luc was provided by Dr. Chiung-Tong Chen (Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Taiwan). All cell lines were authenticated at National Cheng Kung University Center for Genomic Medicine (Tainan, Taiwan) using short tandem repeat (STR) analysis. MRC5, IMR90, A549 and PC-14 were maintained in DMEM media (Gibco, Invitrogen); H460-luc was cultured in RPMI1640 media (Gibco). All media were supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Gibco).
Ethics statement
All animals were obtained from the National Laboratory Animal Center (Republic of China, Taiwan) with the approval of Institutional Animal Care and Use Committee (IACUC), National Cheng Kung University (IACUC approval no. 103195) and were maintained in pathogen-free conditions.
In vivo antitumor growth assay: subcutaneous xenograft and lung orthotopic models For subcutaneous xenograft model, 6-week-old male BALB/c nude mice were subcutaneously implanted with 1 3 10 6 H460-luc cells in 0.1 ml Matrigel per mouse. When tumor xenograft volume reached 50 mm 3 , animals were injected intraperitoneally with SAHA (50 mg/kg), TMU-35435 (50 mg/kg) on Days 1, 3 and 5 for 3 weeks. For combined treatment of TMU-35435 and 5-aza-dC, tumor-bearing mice were injected intraperitoneally with TMU-35435 (25 mg/kg) three times a week and 5-aza-dC (1.5 mg/kg) once a week for 3 weeks. Mice were weighed and the volume of the xenograft were measured and quantified during drug treatment. The xenograft volume was calculated as (length 3 width square)/2 in mm 3 . A total of seven mice per group were analyzed. For lung orthotopic model, 6-week-old BALB/c nude mice were intratracheally instilled with H460-luc cells ( 
Drug combination analysis
Drug interactions were analyzed using the Calcusyn software package (BioSoft), which is based on the median effect model described previously. 23 A combination index (CI) of 1 indicated an additive drug interaction, whereas a CI of >1 was antagonistic and a score lower than 1 was synergistic.
Additional methods
Detailed descriptions of HDAC activity assay, MTT cell cytotoxicity, FLOW cell cycle analysis, RNA extraction and quantitative reverse transcription-polymerase chain reaction (qRT-PCR), DNA extraction, sodium bisulfite conversion and quantitative methylation-specific polymerase chain reaction (qMSP), pyrosequencing, Western blot analysis, immunohistochemistry staining, blood biochemistry and hematology tests, and statistical analyses used in this study are available in Supporting Information Material and Methods. The antibodies used and blotting information are listed in Supporting Information Table 1 . The primer sequences and PCR condition for qRT-PCR are listed in Supporting Information Table  2 .
Results
TMU-35435 is a potent HDAC inhibitor and shows cancer cell-specific cytotoxicity
We developed the compound TMU-35435 with three pharmacophores including a zinc-chelating hydroxamate, a hydrophobic aliphatic chain linker and an acridine as a hydrophobic cap (Fig. 1a, left) . TMU-35435 showed better or comparable inhibitory effects on total HDAC activity and isoform-specific HDAC activity when compared to FDAapproved HDAC inhibitor SAHA (Fig. 1a, right) as assessed by in vitro HDAC fluorometric activity assay. Notably, TMU-35435 was a more potent inhibitor of HDAC8 and HDAC6 than SAHA. For example, TMU-35435 inhibited HDAC6 with an IC 50 value of 3.7 nM, which was 23-127-fold lower than that of other isoforms examined (HDAC1, 156 nM; HDAC2, 470 nM; HDAC3, 86 nM; HDAC8, 214 nM). To further determine whether TMU-35435 inhibited HDAC activity in live cells, human NSCLC cell lines PC-14, A549, A549-Oct4 and H460-luc were treated with TMU-35435 at indicated times and doses to examine the acetylation level of HDAC target proteins. TMU-35435 induced acetylation of histones H3 and H4, and nonhistone protein tubulin in both dose-dependent (Fig. 1b, upper) and time-dependent manners (Fig. 1b, lower) in all the cell lines tested. In addition, TMU-35435 induced acetylation of Hsp90, an HDAC6-related biomarker, in A549 and H460-luc cells (Supporting Information Fig. S1 ). Consistently, TMU-35435 promoted higher extents of protein acetylation in all cells compared to SAHA treatment.
To determine the cancer-specific cytotoxicity of TMU-35435, two normal human lung cell lines MRC5 and IMR90 and four human NSCLC cell lines PC-14, A549, A549-Oct4 and H460-luc were treated with various doses of TMU-35435 for 48 hr and then subjected to MTT cell viability assay. A549-Oct4 is a SAHA-resistant cell line, which exhibits cancer stem cell-like properties by stable overexpression of Oct4 stemness transcription factor as demonstrated in our previous study. 22 As shown in Figure 1c , TMU-35435 significantly induced cytotoxicity of NSCLC cell lines with extrapolated IC 50 value of 3.0-7.5 lM, without showing apparent cytotoxicity towards MRC5 and IMR90 normal lung cell lines. Interestingly, A549-Oct4 and H460-luc cells were more sensitive to TMU-35435 in terms of cell viability as compared with SAHA treatment (Fig. 1c) . These data suggested that TMU-35435 is a potent HDAC inhibitor with cancer-specific cytotoxicity.
TMU-35435 induces G2/M arrest and intrinsic/ mitochondrial-mediated apoptosis in vitro
To evaluate whether the anticancer growth effect of TMU-35435 was due to cell cycle arrest and apoptosis, A549, PC-14 and H460-luc cells were treated with 13 IC 50 or 23 IC 50 doses of TMU-35435 for 48 and 72 hr, followed by flow cytometry analysis using propidium iodide (PI) staining. The results showed that TMU-35435 significantly induced G2/M arrest at 48 hr in A549 and PC-14 and at 72 hr in H460-luc cells ( Fig. 2a and Supporting Information Fig. S2 ). TMU-35435 triggered apoptosis after 72 hr treatment as evident by PI and Annexin V costaining data (Fig. 2b, right) obtained by combining the early apoptosis fraction (PI-/Annexin V1) and late apoptosis fraction (PI1/Annexin V1) cells (Fig. 2b,  left) .
To further delineate the mechanism of TMU-35435-induced apoptosis, Western blot was performed to examine the expression of apoptosis-related proteins in A549, PC-14 and H460-luc cells treated with TMU-35435 in a dose- (Fig.  2c ) or time-(Supporting Information Fig. S3 ) dependent manner. Down-regulation of antiapoptotic protein Bcl-XL was observed in concordance with up-regulation of proapoptotic proteins Bad and Bak in TMU-35435-treated A549, PC-14 and H460-luc cells. In addition, the cleaved form of caspase 9 was accompanied by cleavage of the apoptosis executor caspase 3 upon TMU-35435 treatment for 24 hr. No caspase 8 cleavage was observed following TMU-35435 treatment. These data suggested that TMU-35435 induces NSCLC cell death via intrinsic/mitochondrial-mediated apoptosis but not the extrinsic apoptosis pathway. The immunoblots of SAHA treatment were shown as comparison.
TMU-35435 inhibits tumor growth with safety features in vivo
Next, we conducted assays to evaluate the antitumor growth effects of TMU-35435 in BALB/c nude mice bearing H460-luc xenograft model. Animals were treated with either 50 mg/kg of TMU-35435 or SAHA through intraperitoneal injection. SAHA treatment served as a control. Three injections of TMU-35435 and SAHA were given per week for a total of 3 weeks. Tumor size and body weight were measured for each animal from the beginning of drug treatment to the 21st day. Figures 3a and 3b show the tumor volume and xenograft weight of each experiment group. Notably, H460-luc xenograft was sensitive to TMU-35435 treatment as compared to SAHA treatment. The body weight as well as the hematology and biochemistry analyses of blood samples from tested animals showed no apparent adverse effects compared with DMSO solvent control (Figs. 3c and 3d ). In addition, the H&E staining did not show significant organ damage in spleen, liver and kidney dissected from TMU-35435-treated mice (Fig. 3e) . Figures 3f and 3g show the pharmacokinetic profile of TMU-35435 in plasma quantified with LC/MS/MS. TMU-35435 concentration in plasma slowly declined after injection and remained detectable after 240 minutes. The half-life of TMU-35435 was 15 minutes, area under curve (AUC) was 52859 ng 3 min/ml, the mean residence time (MRT) was 22 minutes. The data suggested that TMU-35435 treatment inhibits tumor growth with safety features.
Orthotopic models are shown to be more relevant to evaluate chemotherapeutics and other therapies for human lung cancer. 24 We created orthotopic lung tumor model by intratracheal injection of H460-luc cells into the lungs to study the effect of TMU-35435 on tumors. TMU-35435 and DMSO treatments began after 3 weeks of tumor inoculation. Mice were injected intraperitoneally with 25 mg/kg TMU-35435, 3 days/week for 4 weeks. Lungs of treated mice were then isolated and photographed using IVIS imaging system. As shown in Supporting Information Fig. S4 , TMU-35435 treatment inhibited lung orthotopic tumor growth by 70%, compared with DMSO control. No body weight loss and no adverse effects on liver and kidney functions were observed compared with solvent control. In addition, the H&E staining did not show significant organ damage in spleen, liver, kidney, lung and brain dissected from TMU-35435-treated mice. Together, the data suggested that TMU-35435 treatment inhibits lung tumor growth, with no detectable toxicity in treated animals.
Expression microarray analysis reveals the TMU-35435 unique anticancer pathways compared to SAHA
To interrogate the unique cancer pathway genes altered by TMU-35435, we performed cDNA expression microarray in A549 cells treated with solvent control, IC 50 dose of TMU-35435 (8 and 24 hr) or SAHA (24 hr). Genes whose expression levels increased more than twofold compared to solvent control upon drug treatment were selected. Integration analysis showed that 754 genes were reactivated by both TMU-35435 and SAHA treatments, while a total 1665 genes were uniquely induced by TMU-35435 treatment (Fig. 4a) .
To gain insight into the functional roles of unique TMU-35435-induced genes, we conducted Ingenuity-IPA pathway analysis and Gene Ontology (GO) analysis. Ingenuity-IPA analysis showed that "Cancer" and "Cell death and survival" were most enriched in the top five diseases and molecular functions, respectively (Fig. 4b) . In addition, GO analysis indicated that the unique TMU-35435-induced genes played important roles in many biological processes, including "negative regulation of cell proliferation (47 genes)" and "Wnt receptor signaling pathway (22 genes)" (Fig. 4c) . Interestingly, the 47 genes involved in "negative regulation of cell proliferation" worked cooperatively to form a functional network (Fig. 4d) . Note that several well-known TSGs were found to be involved in the network, such as AXIN2, IL1A, PML, PPARG, RARb and RUNX3 (Fig. 4d) .
Importantly, we found that many genes participating in "Wnt receptor signaling pathway" were negative regulators of Wnt signaling, such as E-Cadherin, SFRP4, b-TrCP, AXIN2, RARb and CTNNBIP1, suggesting that TMU-35435 could suppress Wnt oncogenic signaling. Since our cDNA expression microarray data were derived from A549 cells, we performed qRT-PCR on H460-luc cell line to cross-validate the unique cancer pathway genes altered by TMU-35435. Our qRT-PCR analysis confirmed that these Wnt negative regulator genes were significantly reactivated in H460-luc cells upon TMU-35435 treatment but not upon SAHA treatment (Fig. 4e) . The inhibition of Wnt signaling by TMU-35435 treatment was evident by the reduced expression of Wnt downstream genes, such as Cyclin D1, c-Jun and c-myc (Fig. 1f) . In addition, we validated the other two TSGs, PTEN and RUNX3, which were reactivated upon TMU-35435 treatment but not SAHA treatment (Fig. 4g) . The above-mentioned genes were also validated in PC-14 and A549 lung cancer cells (Supporting Information Fig. S5 ). Reactivation of PTEN mRNA expression prompted us to test whether PI3K/AKT was inhibited by TMU-35435. Western blot analyses validated up-regulation of PTEN protein in concordance with down-regulation of phorphorylation of AKT at serine-473 and threnione-308 in TMU-35435-treated cells (Fig. 4h) . Taken together, these results suggested that TMU-35435 treatment specifically activates unique networks including many known TSGs and inhibits Wnt signaling pathway leading to tumor suppression.
Combination treatment of TMU-35435 and 5-aza-dC shows a synergistic anticancer effect through reexpression of silenced TSGs in vitro
We were interested to find out whether there was any synergistic or additive effect of TMU-35435 when combined with 5-aza-dC, another clinically used epigenetic inhibitor which results in DNA demethylation and gene reexpression. To this end, lung cancer cell lines A549, PC-14 and H460-luc were treated with TMU-35435 or 5-aza-dC alone or in combination for 72 hr. As shown in Figure 5a (upper), combined treatment of low dose (60-90% cell viability) of TMU-35435 and 5-aza-dC showed a decreased viability compared with single agent treatment in lung cancer cells by MTT assay. The combination index (CI) were all <1 (Fig. 5a, lower) , suggesting that these compounds together synergistically increased cytotoxicity compared to treatment with TMU-35435 or 5-aza-dC alone. Such combinatorial therapeutics further induced apoptosis signaling to a stronger extent than did single agent treatment (Fig. 5b) .
The combination treatment of HDAC and DNMT inhibitors has been shown to decrease DNA methylation levels of certain TSGs, leading to reactivation of TSGs. Therefore, we conducted qMSP assay to examine promoter methylation status of several TSGs, which are known to be silenced by DNA hypermethylation in lung cancer. Indeed, combined treatment with TMU-35435 and 5-aza-dC resulted in significantly decreased DNA methylation levels of TSGs including ALDH1A3, MGMT, RASSF1A, SFRP1, RUNX3 and SLIT2 tested in A549 (Fig. 5c ) and PC-14 (Supporting Information Fig. S6a ) cells. Concordantly, the mRNA levels of these TSGs were up-regulated by such combination treatment (Fig. 5d and Supporting Information Fig.  S6b) . Reexpression of additional genes in "negative regulation of cell proliferation" and "Wnt receptor signaling pathway" were validated in A549 (Fig. 5d ) and H460-luc cells (Supporting Information Fig. S7 ). These data suggested that combined treatment of TMU-35435 and 5-aza-dC shows a significantly increased cytotoxicity partly through reactivation of TSGs.
Combination of TMU-35435 and 5-aza-dC shows synergistic effects on antitumor growth and gene reexpression in vivo
To characterize the synergistic anticancer effect of TMU-35435 and 5-aza-dC combination therapy in vivo, we established H460-luc tumor xenograft by subcutaneous injection model. One week after injection, tumor-bearing mice were treated with either 25 mg/kg of TMU-35435 or 1.5 mg/ kg of 5-aza-dC alone or together through intraperitoneal injection. DMSO treatment served as a control. Three injections of TMU-35435 or/and one injection of 5-aza-dC were given per week for 3 weeks. Figures 6a and 6b show the tumor size and tumor weight in each experiment group. Notably, combination treatment of TMU-35435 and 5-azadC significantly suppressed tumor growth in comparison with single agent treatment. Using immunohistochemistry, we found that the protein level of cleaved caspase 3 and acetylated histone H3 were elevated in TMU-35435 or 5-aza-dC treatment alone, and the level was further enhanced in the group of combination therapy (Fig. 6c) . No obvious systemic toxicity such as body weight loss, hematology/biochemistry examinations or organ dysfunction measured by major organ morphology was observed in tested animals of combination group and other groups (Supporting Information Fig. S8 ). These results indicated that TMU-35435 shows a synergistic antitumor growth effect when combined with 5-aza-dC in vivo without significant side effects.
To examine whether the combination treatment of TMU-35435 and 5-aza-dC decreased DNA methylation levels of certain TSGs, leading to reactivation of TSGs in vivo, we conducted qMSP assay to examine promoter methylation status of several TSGs (Fig. 6c, upper) and qRT-PCR to examine the mRNA levels of these TSGs in xenograft tissues (Fig. 6c,  lower) . The data suggested that combined treatment of TMU-35435 and 5-aza-dC shows significantly increased cytotoxicity partly through reactivation of TSGs in vivo, which corroborated with the results in vitro (Fig. 5 and Supporting Information Figs. S6 and S7 ). These results indicated that TMU-35435 in combination with 5-Aza shows a synergistic antitumor growth effect in vivo via additional DNA demethylation and gene reexpression.
Discussion
In this study, we demonstrated that TMU-35435, a novel hydroxamate-based compound, is a potential HDAC inhibitor for NSCLC treatment through in vitro and in vivo studies. TMU-35435 targeted different members of classes I and II HDACs in vitro and showed HDAC inhibition ability in cellbased and animal studies. TMU-35435 exerted cancer-specific cytotoxicity via cell cycle arrest at the G2/M and subsequently led to mitochondria-mediated apoptosis. Our cDNA expression microarray revealed that TMU-35435 treatment specifically activated unique networks comprising many TSGs and inhibited Wnt signaling pathway resulting in tumor suppression (Supporting Information Fig. S9a) . We further demonstrated that cotreatment of TMU-35435 and 5-aza-dC induced cell death, in part by decreasing DNA methylation levels and leading to reactivation of TSGs including those encoding negative regulators of Wnt signaling pathway in vitro and in vivo. Notably, TMU-35435 treatment alone or in combination with 5-aza-dC did not show significant changes in body weight, organ pathology and hematology/biochemistry examinations of treated mice (Supporting Information  Fig. S9b ). These results demonstrated that TMU-35435 is a potential HDAC inhibitor in lung cancer treatment as a single agent or in combination with 5-aza-dC.
cDNA expression microarray and GO pathway analyses revealed that TMU-35435-induced genes were negative regulators participating in "Wnt receptor signaling pathway", such as E-Cadherin, SFRP4, b-TrCP, AXIN2, RARb and CTNNBIP1, suggesting that TMU-35435 could suppress Wnt signaling. Notably, our GO analysis indicated that the SAHA-induced genes played roles in many biological processes, but not in "Wnt receptor signaling pathway". qRT-PCR analysis confirmed that these Wnt negative regulator genes were significantly reactivated upon TMU-35435 treatment in all NSCLC cells examined. However, the time of reexpression varied for these genes in a cell-type-specific manner. For example, E-Cadherin, SFRP4, b-TrCP, AXIN2 and RARb were upregulated at 8 hr and the level of expression further increased at 24 hr in PC-14 cells, while such a gradual upregulation pattern was only observed for E-Cadherin in A549 cells. Of note, b-TrCP and CTNNBIP1 were upregulated at 8 hr then dropped to basal level at 24 hr in A549 cells; while such a pattern could be only seen for CTNNBIP1 in PC-14 cells. The cell-specific reexpression pattern induced by TMU-35435 suggests that the tumorigenesis of each cancer cell is controlled by different epigenetic mechanisms. [25] [26] [27] For example, the compact chromatin structures of SFRP4, AXIN2 and RARb could be effectively and sustainably loosened by treating with TMU-35435 for 8 to 24 hr in PC-14, while the chromatin structure of these genes were relatively condensed in A549 so they needed more time to be decompressed by TMU-35435 treatment. Some genes such as CTNNBIP1 may be induced transiently into open chromatin structure by TMU-35435 treatment. Alternatively, their corresponding transcriptional regulators including activators or repressors may be induced by TMU-35435 to change the expression pattern of these originally silenced genes at later time points. The status of chromatin structure and the upstream transcriptional factors of these genes will be further investigated. Notably, reexpression of these Wnt negative regulator genes together with reduced expression of Wnt downstream genes such as Cyclin D1, c-Jun and c-myc confirmed that TMU-35435 suppresses the oncogenic Wnt signal in NCSLC.
The combination treatment with TMU-35435 and 5-azadC potentiating the reactivation of TSGs in our cell-based and xenograft studies, validating the theory of the synergy between DNA methylation and histone acetylation in gene regulation and tumorigenesis. 15, 28 However, the profiles of gene promoter hypermethylation and histone deacetylation differed in each NSCLC cell line. Such a potentiated reactivation of TSGs by TMU-35435 and 5-aza-dC at both DNA demethylation and mRNA reexpression levels could be seen for ALDH1A3 and SLIT2 in A549 cells, RARb and SLIT2 in PC-14 cells, and SFRP1 and RASSF1A in H460-luc xenografts. Of note, additional mRNA reexpression by cotreatment with TMU-35435 and 5-aza-dC was observed for most genes analyzed in NSCLC cells. Similar results have been reported by others. 13, 27 Therefore, the potentiated reexpression of these genes could be mainly contributed by additional decondensation of chromatin structure by cotreatment with TMU-35435 and 5-aza-dC as compared to single agent treatment. It is reported that histone modifications, such as histone deacetylation, are prerequisite for DNA methylation. For example, histone H3 deacetylation and H3K9 trimethylation play important roles in RASSF1A silencing prior to DNA methylation in proliferating human mammary epithelial cells with increasing passage numbers. 29 Nevertheless, DNMTs can directly interact with HDACs to form a repressive complex at gene promoters, thus resulting in chromatin compaction and gene silencing. 30, 31 We will further interrogate more genes in our array dataset to reveal a subset of genes which could be both DNA demethylated and mRNA reexpressed by cotreatment with TMU-35435 and 5-aza-dC.
NSCLC is a disease characterized by both genetic and epigenetic heterogeneity with multiple alterations. Our results suggested that combination therapy with TMU-35435 and 5-azadC may have clinical potential in lung cancer. The combination therapy not only increased the cell death of cancer cell lines, but also the percentage of apoptosis in vivo. A number of HDAC inhibitors have been tested in combination with chemotherapeutic agents such as etoposide and cisplatin in lung cancer patients. 32, 33 These topoisomerase II inhibitors or DNA damage reagents could gain accessibility to target DNA thus increasing the efficacy since TMU-35435 induces open chromatin structure. In addition, it warrants further investigation whether TMU-35435 alone or in combination with other drugs could be used for overcoming the acquired resistance seen in most NSCLC patients who initially respond to EGFR TKI therapy or chemotherapy. [34] [35] [36] It is likely that combined epigenetic therapy could result in increased antitumor activity in comparison to the use of single-agent inhibitor of DNMTs or HDACs, but this needs validation in randomized studies.
Conclusion
Our studies show that TMU-35435 is a novel HDAC inhibitor that exerts anticancer activities in NSCLC cells and animal models. Enhanced expression of genes inhibiting Wnt oncogenic pathway is involved in antitumor growth effect of TMU-35435. Combined TMU-35435 with 5-aza-dC treatment shows synergistic anticancer effects compared to treatment with either single agent. The pharmacokinetic properties and safety features of TMU-35435 indicate that TMU-35435 is a potent HDAC inhibitor. Many HDAC inhibitors in clinical use, including SAHA, are oral drugs. TMU-35435 could be optimized to improve oral bioavailability and to increase its clinical value in lung cancer treatment.
